CN102526274A - Traditional Chinese medicine for treating chronic hepatitis and hepatic fibrosis - Google Patents
Traditional Chinese medicine for treating chronic hepatitis and hepatic fibrosis Download PDFInfo
- Publication number
- CN102526274A CN102526274A CN2010106184123A CN201010618412A CN102526274A CN 102526274 A CN102526274 A CN 102526274A CN 2010106184123 A CN2010106184123 A CN 2010106184123A CN 201010618412 A CN201010618412 A CN 201010618412A CN 102526274 A CN102526274 A CN 102526274A
- Authority
- CN
- China
- Prior art keywords
- xanthorrhiza
- sheet
- chinese medicine
- liver
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Images
Landscapes
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
The invention discloses a traditional Chinese medicine for treating chronic hepatitis and hepatic fibrosis, wherein Prismatomeria tetrandra tablets are fully utilized, and the traditional Chinese medicine is characterized by applying the Prismatomeria tetrandra tablets to preparation of a medicine for treating the chronic hepatitis and/ hepatic fibrosis. The traditional Chinese medicine disclosed by the invention is capable of treating patients suffering from the chronic hepatitis and the hepatic fibrosis by sufficiently utilizing the Chinese patent medicine, namely the Prismatomeria tetrandra tablets; the traditional Chinese medicine has the advantages of convenience for application, obvious effect, safety, reliability and no obvious adverse effect and toxic and side effects and is favorable for enlarging the indication range of the Prismatomeria tetrandra tablets, opening up a novel purpose for application of the Prismatomeria tetrandra tablets and greatly saving cost for researching and developing hepatopathy treating medicines and treating hepatopathy; furthermore, a production process of the Prismatomeria tetrandra tablets is simple and has a low cost; and a due contribution is made to make mass ordinary people capable of seeing doctors and affording medicines.
Description
Technical field
The present invention relates to a kind of Chinese medicine, in particular for the Chinese medicine of treatment hepatopathy,
Background technology
At present, worldwide, chronic hepatitis, liver cirrhosis become the major disease that is only second to cardiovascular and cerebrovascular disease and malignant tumor, and be very harmful to the mankind, and China's number of the infected is respectively 4,000 ten thousand people and about 1,000,000.Hepatic fibrosis is the commitment of liver cirrhosis, is chronic hepatopathy the only way which must be passed to the liver cirrhosis development.Hepatic fibrosis still had the reverse possibility before getting into liver cirrhosis, still do not have ideal Therapeutic Method for hepatic fibrosis both at home and abroad so far.Therefore, seeking effective medicine, block, delay and the generation and the development that reverse hepatic fibrosis is the world of medicine's problem anxious to be solved, is the key point of control liver cirrhosis.Up to now, the treatment of doctor trained in Western medicine anti-hepatic fibrosis mainly is to establish the anti-hepatic fibrosis approach to each link of the hepatic fibrosis generating process of having illustrated, and the medicine majority of having reported is to be in the experimentation stage.Try out at present in clinical medicine and mainly contain colchicine, interferon, proline analogs, Malotilate, adrenocortical hormone etc.But it is undesirable because of effect of anti hepatic fibrosis that these medicines have, and the side effect that has is big, have because of costing an arm and a leg, be difficult to accepted by numerous patients.(5) at present efficient and low toxicity, the little anti-hepatic fibrosis Western medicine of side effect do not come out yet.
Closely during the last ten years, many scholars study Chinese medicine prevention chronic hepatitis, hepatic fibrosis, find that Chinese medicine has better effects to chronic hepatitis and hepatic fibrosis.Conventional Chinese medicine and Chinese medicine extract have Radix Stephaniae Tetrandrae first element, amygdalin, matrine, emodin, Cordyceps polysaccharide etc.Compound Chinese medicinal preparation has supporting vital QI and dispersing blood stasis side, 861 electuaries, little bupleurum preparation, the fine electuary of change liver, soothing the liver reason spleen sheet, Cacumen Securinegae Suffruticosae capsule or the like that certain anti-fibrosis effect that protects the liver is all arranged; But it is still rare that particular significant effect is stood multiple report, and majority is not applied for a patent.Existing patented technology has 20310111205.9; 208100042941.6; 20071005136.; 99113887.2 Deng though anti-liver injury, effect of anti hepatic fibrosis are arranged, be mostly big compound recipe, complicated component, price is higher.The effect that has is not obvious.
Xanthorrhiza has another name called that South Mountain is colored, Os Canitis is wooden.For the root of Maguireothamnus speciosus South Mountain flower (Prismatomeris comatar.z.Run), be one of Guangxi each medical material of special product characteristic.Strong root bone strengthening is arranged, dampness removing jaundice eliminating, promoting tissue regeneration by removing blood stasis, the merit of cooling blood for hemostasis.The Guangxi national folk is in order to various diseases such as treatment rheumatic bone-setting, hepatitis pneumosilicosis, anemias.It contains organo-aluminum compound, Rubiadin, β-each sterol and anthracene class modern study.Guangxi YingKang Pharmaceutical Co., Ltd has been developed to the xanthorrhiza sheet of treatment pneumosilicosis, at home and abroad sells.The xanthorrhiza sheet is the old brand product that Guangxi YingKang Pharmaceutical Co., Ltd obtains the accurate font size certification of national medicine already, and the xanthorrhiza sheet is the medicine that state approval is produced, and batch code is: the accurate word Z45020305 of traditional Chinese medicines.The producer that has produced the xanthorrhiza sheet comprises Guangxi YingKang Pharmaceutical Co., Ltd.Former certification indication has only " treatment pneumosilicosis ".Enlarging indication is well worth doing.
Summary of the invention
It is simple to the purpose of this invention is to provide a kind of production technology, and determined curative effect, cost hang down the Chinese patent medicine with folk prescription treatment chronic hepatitis, hepatic fibrosis.
In recent years, the applicant is in order to understand and to verify the therapeutical effect of xanthorrhiza sheet to chronic hepatitis, hepatic fibrosis.The applicant has carried out pharmacodynamic experiment research to animal respectively with the xanthorrhiza sheet, and 60 routine patients have been carried out clinical observation.With multiple hepatitis, chronic hepatitiss such as xanthorrhiza sheet treatment hepatitis B, its effective percentage 88.3%, liver function recovery natural rate of interest 85%, and take for a long time and have no side effect.After this we carry out preliminary anti-liver injury, Fibrotic experimentation to the xanthorrhiza sheet, and the result proves: the xanthorrhiza sheet is no matter be that serology detection or pathological observation all have tangible anti-hepatitis, effect of anti hepatic fibrosis.Therefore, the xanthorrhiza sheet is treated the pneumosilicosis except being used for, and can also be used to treat the liver function injury due to the chronic hepatitis, and the transaminase increases and hypochondriac pain, poor appetite, disease person such as weak.Simultaneously to carbon tetrachloride (CCL
4) the rat liver fibrosis effect of having clear improvement of complex factors improved method preparation.
Technical scheme of the present invention is:
A kind of Chinese medicine of treating chronic hepatitis, hepatic fibrosis, it has made full use of the xanthorrhiza sheet, it is characterized in that:
The application of xanthorrhiza sheet in preparation treatment chronic hepatitis and/hepatic fibrosis medicines.
The preparation of existing xanthorrhiza sheet is simple, and [method for making] got xanthorrhiza, extract three times with 60% alcohol heating reflux, and each 2 hours, merge extractive liquid; Filter, decompression filtrate recycling ethanol is concentrated into the thick paste shape, divides with 10 times of amount warm water to stir for three times, leaves standstill; Filter, filtrate decompression concentrates, and vacuum drying is pulverized, and adds appropriate amount of auxiliary materials; The system granule is pressed into 1000, and sugar coating promptly gets.
[character] these article are coated tablet, remove to show pitchy behind the sugar-coat; Mildly bitter flavor, puckery.
[function with cure mainly] active eliminating stagnation, promoting tissue regeneration by removing blood stasis, strong muscles and bones has anti-silicon dioxide cytotoxicity.Be used to treat pneumosilicosis.
In order to understand and to verify the therapeutical effect of xanthorrhiza sheet to chronic hepatitis, hepatic fibrosis.The applicant has carried out pharmacodynamic experiment research to animal respectively with the xanthorrhiza sheet, and 60 routine patients have been carried out clinical observation.The result shows that the xanthorrhiza sheet is treated the pneumosilicosis except being used for, and can also be used to treat the liver function injury due to the chronic hepatitis, and the transaminase increases and hypochondriac pain, poor appetite, disease person such as weak.Simultaneously to carbon tetrachloride (CCL
4) the rat liver fibrosis effect of having clear improvement of complex factors improved method preparation.
Can know from above research and practice; The present invention has made full use of existing Chinese patent medicine xanthorrhiza sheet and just can treat chronic hepatitis, patients with liver fibrosis, and effect easy to use is remarkable, and is safe and reliable; No obvious adverse reaction and toxic and side effects; Enlarged the indication of xanthorrhiza sheet, opened up new purposes, saved the expense of research and development of treatment liver disease drug and liver disease greatly for the application of xanthorrhiza sheet.And the production technology of xanthorrhiza sheet is simple, and cost is low.For thinking highly of disease and afford medicine, the general common people made due contribution.
Description of drawings
Fig. 1 is that the present invention tests blank control group liver tissues of rats structure pathological section figure.
Fig. 2 is experimental model group liver tissues of rats structure pathological section figure of the present invention.
Fig. 3 is that the present invention tests colchicine group liver tissues of rats structure pathological section figure.
Fig. 4 is that the present invention tests xanthorrhiza sheet high dose group liver tissues of rats structure pathological section figure.
Fig. 5 is that the present invention tests dose groups liver tissues of rats structure pathological section figure in the xanthorrhiza sheet.
Fig. 6 is that the present invention tests xanthorrhiza sheet low dose group liver tissues of rats structure pathological section figure.
The specific embodiment
Below in conjunction with accompanying drawing, the present invention is described further.
Be to understand the therapeutical effect of xanthorrhiza sheet to hepatopathy, the applicant has obtained effect preferably to the research that experimentizes of xanthorrhiza function for protecting liver and reducing enzyme activity.Specific as follows:
One, carries out the experimentation of xanthorrhiza sheet function for protecting liver and reducing enzyme activity
1, experiment material:
(1) medicine
1. xanthorrhiza sheet: every 0.2g is provided by Guangxi YingKang Pharmaceutical Co., Ltd of this problem cooperation unit group.Be made into the desired concn oral liquid with distilled water during experiment.
2. HUGAN PIAN is produced by Guangdong Huizhou pharmaceutcal corporation, Ltd.Be mixed with the desired concn oral liquid with distilled water during experiment.
3. AST, ACT test kit, Changchun Bioisystech Co., Ltd produces, CCL
4Analytical pure, chemical reagent factory in Chongqing produces.
(2) animal
The SD rat, male and female half and half, female do not produce and do not have pregnant, body weight 120～150g.Laboratory animal room of Guangxi Medical University provides.
2, experimental technique:
Get 60 of above-mentioned healthy white rats, be divided into six groups of A, B, C, D, E, F at random.The A group is the normal control group, and the B group is model group: rat skin lower injection CCL
4By conventional modeling, C group is HUGAN PIAN matched group (hereinafter to be referred as the HUGAN PIAN group), D, E, F group be respectively the xanthorrhiza sheet little, in, big three dose groups.Every group of 10 rats.A, B group are regularly irritated stomach once with the equal-volume normal saline every day; The C group is irritated stomach once with HUGAN PIAN 2.97g/Kg every day simultaneously; D, E, F group are irritated stomach once, all continuous 4 days with xanthorrhiza sheet 1.4g, 2.8g, 5.6g (dried cream)/kg respectively every day simultaneously.To the 4th day gastric infusion 1 hour, A organized every Mus with equal-volume normal saline lumbar injection once; B, C, D, E, F organize every Mus and use 10%CCL
4Peanut oil solution 5ml/kg lumbar injection once.In lumbar injection CCL
4Back 48 hours (because of CCL
4Poison back 48 hours ALT, AST reach the peak) the sacrificed by decapitation all animals, collect blood, separation of serum is surveyed ALT, AST; Every animal is got the roughly the same fritter hepatic tissue of same liver and position and does check pathological section.
3, experimental result:
(1) ALT, AST detection case: see table 1
Table 1 xanthorrhiza sheet is to rat CCL
4Acute liver damage ALT, AST influence (X ± SD)
* show and CCl
4Poisoning group relatively P＜0.5** is shown and CCl
4The poisoning group is P＜0.01 relatively
Experimental result shows: CCl
4Poisoned simple CCl back 48 hours
4Poisoning group ALT, AST activity are all high than other 5 groups.The ALT level: HUGAN PIAN group and treatment group small dose group compare with the poisoning group respectively, significant difference (P＜0.05).The heavy dose of group of treatment group compares difference highly significant (P＜0.01) with the poisoning group; The AST level: HUGAN PIAN group and poisoning group compare, difference highly significant (P＜0.01).Middle and high dose groups of xanthorrhiza sheet and poisoning group comparing difference be (P＜0.01) significantly.Finding from table 8, the xanthorrhiza sheet seemingly has a certain amount of effect relationship to the influence of ALT, AST, but statistical procedures does not have significant difference (P＞0.05), and three dose groups of xanthorrhiza sheet and HUGAN PIAN group compare each other, also do not have significant difference (P＞0.05).The above results prompting xanthorrhiza sheet and HUGAN PIAN all can significantly reduce CCl
4The ALT of Rats with Acute Liver Injury, AST activity have certain protective role to the damage hepatocyte.
(2) hepatic pathology histological examination situation: by the pathology requirement; The liver of every rat is carried out the complete observation of index of correlation (being hepatocyte endochylema puffing, cloudy swelling, fat change, water degeneration, acidophilia's change, necrosis, cell infiltration, Kupffer hypertrophy, congestion, hemorrhage, silt gallbladder), see simple CCl
4Whole rats are organized in poisoning all has hepatic necrosis and cell infiltration, and all heavy than all the other test group; Positive drug HUGAN PIAN group hepatocyte endochylema puffing, steatosis, water degeneration, acidophilia change lighter than model group.The heavy dose of group of xanthorrhiza sheet hepatocyte endochylema puffing than in, small dose group lacks, and fat-free degeneration.The result shows: 1. each dose groups rat liver of xanthorrhiza sheet is lighter than the pathological changes of model group; 2. the degeneration of the heavy dose of group of xanthorrhiza sheet rat hepatocytes than in, small dose group is little.
In sum, xanthorrhiza sheet treatment CCl
4Acute liver damage has certain enzyme curative effect of falling.The hepatocellular degeneration of heavy dose of group than in, small dose group lacks, and points out the xanthorrhiza sheet that liver protection effect is arranged, and is better with heavy dose group effect especially.
Above-mentioned xanthorrhiza sheet to the research of the therapeutical effect of hepatopathy in reference to following document: 1, Xu Shuyun etc., pharmacological experimental methodology People's Health Publisher, 2002,1346.2, clothing flower bud, Yang Junsheng. the treatment by Chinese herbs hepatic fibrosis makes progress Chinese Chinese medicine information magazine 2006,13 (7): 90.
Two, carry out the experimentation of xanthorrhiza sheet anti-hepatic fibrosis
For understanding the effect of xanthorrhiza sheet anti-hepatic fibrosis, Chinese medicine xanthorrhiza sheet has been carried out pharmacological testing.Adopt carbon tetrachloride (CCL
4) the complex factors improved method prepares the rat liver fibrosis model, gives the high, medium and low dosage of Chinese medicine xanthorrhiza sheet respectively and treats, observe its effect of anti hepatic fibrosis and compare with blank group and positive controls.Result: compare with blank control group; Model group rat liver index increases, and Serum ALT, AST content significantly raise, and ALB content reduces; Difference has significance (P＜0.01); And pathology shows the hepatocyte arrangement disorder, the degeneration of hepatocyte cavity appearance, necrosis, and a large amount of proliferations of fibrous tissue in portal area also are dispersed in inflammatory cell infiltration; Compare with model group, Chinese medicine xanthorrhiza sheet high dose group rat ALB content obviously raises (P＜0.05), and the hepatocellular degeneration necrosis significantly alleviates.Conclusion: Chinese medicine xanthorrhiza sheet high dose (the dried cream of 5.6g/kg) to carbon tetrachloride (CCL
4) the rat liver fibrosis effect of having clear improvement of complex factors improved method preparation.
1, tests purpose
Observe Chinese medicine xanthorrhiza sheet effect of anti hepatic fibrosis.
2, material
(1) laboratory animal SD rat is 60, the SPF level, and body weight 220 ± 30g, male.Available from Guangxi Chinese medicine academy Experimental Animal Center.Raise in 20～25 ℃, relative humidity 60 ± 10% environment.
(2) medicine and reagent Chinese medicine xanthorrhiza sheet, lot number: 100101, the yellow film coated tablet; Provide by Guangxi YingKang Pharmaceutical Co., Ltd, the every dried cream 2g of drug, clinical Coming-of-Age Day consumption be each 6; Be equivalent to the dried cream of 24g/sky every day 3 times, faces the time spent to be formulated as desired concn with distilled water; The colchicine sheet, Haobang Pharmaceutical Co., Ltd., Yunnan produces, lot number: 090920; Aspartate amino transferase is measured test kit (AST) test kit, kit for determining alanine aminopherase (ALT) and albumin reagent box (ALB) and is the production of Changchun remittance power Bioisystech Co., Ltd, lot number difference: 2010002,2010002,2010003.
(3) instrument BS224S type electronic balance (Beijing Sai Duolisi); AMS-18A automatic clinical chemistry analyzer (Beijing Ao Pusen); SW-261-79 type electric heating constant temperature water bath (Shanghai Medical Apparatus and Instruments Factory)
3, method and result
(1) the method male SD rat is 60, is divided into 6 groups at random: blank control group, model group, the high, medium and low dose groups of Chinese medicine xanthorrhiza sheet, colchicine group, 10 every group.Modeling method: except that blank control group, all the other each groups are used carbon tetrachloride (CCL
4) the complex factors improved method prepares the rat liver fibrosis model, modeling begins 2w and gives high fat, low-protein mixed feed (20% Adeps Sus domestica+80% Semen Maydis powder), uses normal diet behind the 2w instead, normally drinking-water, twice lumbar injection 50%CCL weekly during the modeling
4Peanut oil solution 0.1ml/100g body weight, blank control group are given lumbar injection respective volume peanut oil solution, 6 week back Cheng Mo.Medication: from modeling the 1st day, the high, medium and low dose groups of Chinese medicine xanthorrhiza sheet was pressed the dosed administration of the dried cream/kg of 5.6g, the dried cream/kg of 2.8g, the dried cream/kg of 1.4g respectively; The colchicine group is pressed the 0.2mg/kg dosed administration.Each group is irritated gastric capacity and is the 10ml/kg body weight, and blank control group, model group are given the equal-volume distilled water respectively, irritate stomach every day 1 time, totally 6 weeks.Each organizes fasting (can't help water) 12h after the last administration, weighs, and anaesthetizes through 35mg/kg body weight pentobarbital sodium; The ventral aorta blood sampling; Room temperature leaves standstill 1.5h, and the centrifugal 15min of 2500rpm gets serum and adopts automatic clinical chemistry analyzer to measure the content of Serum ALT, AST, ALB; Rat is put to death in the blood sampling back, cuts open and gets liver, weighs, and calculates liver index (organ index=organ weights/body weight * 100); Liver lobus sinister BIAO and BEN fixedly carries out HE dyeing with 10% formalin solution, and light microscopic is observed the hyperplasia degree of hepatic fibrosis down.
(2) the statistical analysis experimental data all adopts SPSS 13.0 statistical packages to handle; Observation index is expression with
; Relatively do not adopt variance analysis and t check between on the same group; P＜0.05 expression difference has significance, has statistical significance.
(3) result
A, Chinese medicine xanthorrhiza sheet are to the exponential influence of hepatic fibrosis rats liver
Compare with blank control group, model group and each medication group rat liver index all obviously increase, and significant difference (P＜0.01) is arranged; Compare with model group, colchicine group rat liver index significantly reduces, and difference has significance (P＜0.05), and prompting rat liver fibrosis model prepares successfully.The result sees table 1.
Table 1 Chinese medicine xanthorrhiza sheet is to the exponential influence of hepatic fibrosis rats liver
Annotate: compare with blank control group,
★P＜0.01; Compare with model group,
▲P＜0.05.
B, Chinese medicine xanthorrhiza sheet are to the serological influence of hepatic fibrosis rats
Compare with blank control group, model group and each medication group rat blood serum AST, ALT content obviously raise, and ALB content obviously reduces, and significant difference (P＜0.01) is arranged; Compare with model group; Colchicine group rat AST content reduces; Colchicine group and Chinese medicine xanthorrhiza sheet group ALB content all obviously raise, and difference has significance (P＜0.05 or P＜0.01), and prompting colchicine and Chinese medicine xanthorrhiza sheet high dose group have certain effect of anti hepatic fibrosis.The result sees table 2.
Table 2 Chinese medicine xanthorrhiza sheet is to the serological influence of hepatic fibrosis rats (
n=10)
Annotate: compare with blank control group,
★P＜0.01; Compare with model group,
▲P＜0.05,
▲ ▲P＜0.01.
C, Chinese medicine xanthorrhiza sheet are to the influence of hepatic fibrosis rats hepatic pathology
(a) perusal blank control group rat liver color is scarlet, smooth surface, the crisp softness of matter.Dosage and low dose group rat liver are kermesinus in model group, the Chinese medicine xanthorrhiza sheet, and the surface is graniphyric, the edge rust, and quality is more tough.Colchicine group and Chinese medicine xanthorrhiza sheet high dose group rat liver color are dark red slightly, and the edge is blunt slightly, and quality is tough slightly.
(b) pathology section examination
Shown in Figure 1, be that the present invention tests blank control group liver tissues of rats structure pathological section figure.From figure, can know that the lobules of liver clear in structure is complete in the blank control group liver tissues of rats, the hepatic cords marshalling, no hepatocellular degeneration is downright bad, no cell infiltration, no fibroplasia.
Shown in Figure 2, be experimental model group liver tissues of rats structure pathological section figure of the present invention.From figure, can know; The visible hepatocyte arrangement disorder of model group rat (8) hepatic tissue; The degeneration of hepatocyte cavity appearance, necrosis; The a large amount of proliferations of fibrous tissue in portal area also are dispersed in inflammatory cell infiltration, and the visible proliferation of fibrous tissue of part rat (5) extends to lobules of liver, separates lobules of liver and forms pseudolobuli.
Fig. 3 and shown in Figure 4 is that the present invention tests colchicine group and xanthorrhiza sheet high dose group liver tissues of rats structure pathological section figure.From figure, can know that (8) and high dose group (8) rat hepatocytes degeneration necrosis alleviates; The visible pseudolobuli of 2 rats of colchicine group and 3 rats of high dose group.
Fig. 5 and shown in Figure 6 is that the present invention tests dose groups and low dose group liver tissues of rats structure pathological section figure in the xanthorrhiza sheet.Can know that from figure middle dose groups (7) and low dose group (8) rat hepatocytes degeneration, necrosis are still more obvious, the portal area proliferation of fibrous tissue, part rat (4 of middle dose groups, 4 of low dose group) is it is thus clear that pseudolobuli.
D, conclusion
Chinese medicine xanthorrhiza sheet high dose (the dried cream of 5.6g/kg) to carbon tetrachloride (CCL
4) the rat liver fibrosis effect of having clear improvement of complex factors improved method preparation.
More than in the research of xanthorrhiza sheet effect of anti hepatic fibrosis with reference to following document: [1] Liu Lixin, Shi Yongqiang. drug-induced hepatic fibrosis Progress in Animal Model [J]. Chinese medicine and clinical, 2009,9 (9): 851-853.[2] Guo Meizi, Li Xiaosheng, Shen Dingming, etc. the influence [J] that chrysophanic acid forms rat liver fibrosis. Chinese hepatopathy magazine, 2003,11 (1): 26..[3] Fang Houhua. medical experiment animal pattern [M]. Beijing: military medicine Science Press, 2002:118. [4] Zhang Haiyan, Wen Tao; Lu Jing; Deng. the discussion [J] of tetrachloro-methane induction rat chronic liver injury model method. practical hepatopathy magazine, 2009,12 (3): 161-164.
Three, carry out the xanthorrhiza sheet is treated the clinical observation of chronic hepatitis
In order to confirm effect, 60 routine chronic hepatitis patients are treated with the xanthorrhiza sheet in year October in January, 2009 to 2010 to the people.Clinical observation result proves that the xanthorrhiza sheet has the effect of clearing away heat-damp and promoting diuresis, blood circulation promoting and blood stasis dispelling, alt-reducing and liver-protecting.Can be used for treating liver function injury that chronic hepatitis causes and hypochondriac pain, poor appetite, disease such as weak.60 routine chronic hepatitiss of this group treatment, the tcm symptom effective percentage is 88.3%; Recovering the liver function effective percentage is 85.3%.These article are safe and reliable, no obvious adverse reaction and toxic and side effects.
The xanthorrhiza sheet is the Chinese medicine preparation that Guangxi YingKang Pharmaceutical Co., Ltd produces, and is mainly used in the treatment pneumosilicosis now.The applicant finds that xanthorrhiza has the effect of clearing away heat-damp and promoting diuresis, blood circulation promoting and blood stasis dispelling, alt-reducing and liver-protecting in clinical and investigation.Except being used for treating the pneumosilicosis, can also be used to treat the liver function injury due to the chronic hepatitis, the transaminase increases and hypochondriac pain, poor appetite, disease person such as weak.
For further understanding the effect of its alt-reducing and liver-protecting, we have carried out clinical observation year June in January, 2009 to 2010 to 60 routine chronic hepatitis patients, obtain good result.The existing report as follows:
Clinical data
One, physical data:
The object of observation of including in is 18～65 years old, has the various chronic hepatitis patients of liver function injury.Treat 60 examples altogether, male 37 examples, women 23 examples.In the majority with 37～47 years old.Average course of disease 21 months.
Two, case is selected:
(1), include standard in:
1. laboratory examination shows the various chronic hepatitis patients of liver function injury;
2. Chinese medical discrimination belongs to syndrome of qi stagnation and blood stasis.
(2), exclusion standard:
1, confirms on inspection by drug intoxication or the caused liver function injury person of malignant tumor.
2, the age is at under-18s or over-65s, gestation or women breast-feeding their children.
3, be associated with serious primary disease such as cardiovascular, kidney and hemopoietic system, psychotic.
4, do not meet the standard of including in,, can't judge that curative effect or data are not congruent to affect the treatment or safety judgement person by the regulation medication.
(3), liver function injury diagnostic criteria (formulating :) according to " the clinical research guideline of new Chinese medicine treatment hepatitis "
1, serum total bilirubin (HBIL)＞17umol/L
2, bilirubin direct (DBIL)＞3.42umol/L
3, glutamate pyruvate transaminase (ALT)＞40u (Reitman method)
Three, chronic hepatitis diagnostic criteria:
By nineteen ninety Shanghai meeting standard.
Four, Chinese medical discrimination
Syndrome of qi stagnation and blood stasis (formulating according to " the clinical research guideline of new Chinese medicine treatment viral hepatitis "): appearance is dark and gloomy, and is indigestion and loss of appetite, bitter taste and dryness in the mouth, hypochondriac pain abdominal distention, lassitude, or skin pruritus, yellowish or reddish urine, constipation or half congealed, purplish tongue, stringy and hesitant pulse.
Five, traditional Chinese medical science witness light and heavy degree grade scale:
See the following form 1.
Observational technique:
Observe 60 examples altogether, all use the xanthorrhiza sheet for oral administration, each 5, every day 3 times, 8 weeks of logotype.Routine is made detailed physical examination to the experimenter before the test, surveys liver function, meets case choice criteria person and promptly includes the object of observation in.Weekly with examining 1 time, inquire the situation of taking medicine, the record state of an illness and side effect after taking medicine.Finish the back course of treatment and check liver function in 1 week.Therapeutic effect is evaluated with scoring method, each witness by do not have, light in, remember 0,2,4,6 heavily respectively, divide.The curative effect judgement is directly made by the observer.Viewing duration is without other hepatitis medicaments.The result:
One, curative effect judging standard:
(1), traditional Chinese medical science disease curative effect judging standard:
1, effective: primary symptom is clearly better or disappears, and total mark reduces more than 30%.
2, invalid: as not reach above standard person.
Two, efficacy analysis:
1, the influence of symptoms, sign: see the following form 2.
2, to the influence of liver function: see the following form 3
Untoward reaction:
60 examples are organized in this treatment, are at viewing duration and find obvious adverse reaction and toxic and side effects.
Model case:
Wei XX, male, 32 years old.Live Liang Qing town, Nanning City.The patient went to a doctor on March 6th, 2009 because of poor appetite, hypochondriac pain, sleepy weak half a year.The normal closely over the past half year inappetence of private prosecution, the time have that abdomen is little to expand, body is tired weak, does not give attention.History of virus hepatitis there are 2 years.Have a medical check-up: vital sign is normal, and skin has spider angioma, the cardiopulmonary no abnormality seen.Abdomen is soft, and 2cm touches under the liver rib, in the matter, and smooth surface, mild tenderness, there is percussion pain the hepatic region.Murphy sign (one), spleen does not touch, and body of the tongue is purple, yellow and greasy fur, stringy and thready pulse.Liver function test: TBIL40ummol/L, DBIL 43ummol/L, ALT 90uo HBsAg (+), anti--HBs (-), HBeAg (+), anti--HBe (-), anti-HBc (-).Tcm diagnosis: hypochondriac pain (syndrome of qi stagnation and blood stasis).Western medicine diagnose: chronic hepatitis.Give the treatment of xanthorrhiza sheet, each 5, every day 3 times, 4 weeks of logotype.The 2 all backs liver pain of taking medicine alleviate, and appetite takes a turn for the better.Refreshing tired weak the alleviating in 4 week backs, liver is 1cm under right rib, touches pain, hepatic region tapping pain, spleen does not touch.The back hypochondriac pain disappearance of 6 weeks, the liver spleen does not touch.8 week backs except that still have slight weak, all diseases disappear, the liver spleen does not touch.Liver function test: TBIL 15ummol/L, DBIL3.4ummol/L, ALT36u.Traditional Chinese medical science disease efficacy evaluation: effectively.Liver function efficacy evaluation: effectively.
This is organized selected case and is the chronic hepatitis patient with liver function injury.Disease such as treatment back patient's hypochondriac pain, poor appetite, abdominal distention, heavy sensation of the body, asthenia and liver function all take an evident turn for the better (P＜0.01 sees the following form 3), and prompting xanthorrhiza sheet has the effect of clearing away heat-damp and promoting diuresis, blood circulation promoting and blood stasis dispelling, alt-reducing and liver-protecting.
This organizes 60 examples, effective 53 examples of tcm symptom, and effective percentage is 88.3%; Effective 51 examples of liver function curative effect, effective percentage is 85%.
This organizes 60 routine clinical observations, is to find obvious adverse reaction and toxic and side effects, points out these article safe and reliable.
Conclusion:
The xanthorrhiza sheet has the effect of clearing away heat-damp and promoting diuresis, blood circulation promoting and blood stasis dispelling, alt-reducing and liver-protecting, can be used for the liver function injury that chronic hepatitis causes.60 examples are organized in this treatment, effective 53 examples of symptom, and the tcm symptom effective percentage is 88.3%; Effective 51 examples of liver function curative effect, effective percentage is 85%.
Table 1 disease and untoward reaction light and heavy degree grade scale
Disease integration comparison before and after table 2 treatment (X ± SD)
Liver function test relatively before and after table 3 treatment
Claims (2)
1. Chinese medicine of treating chronic hepatitis, hepatic fibrosis, it has made full use of the xanthorrhiza sheet, it is characterized in that:
The application of xanthorrhiza sheet in preparation treatment chronic hepatitis and/hepatic fibrosis medicines.
2. the Chinese medicine of treatment chronic hepatitis according to claim 1, hepatic fibrosis is characterized in that:
The xanthorrhiza sheet is in preparation treatment pneumosilicosis, and the application in treatment chronic hepatitis and/or the hepatic fibrosis medicines.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2010106184123A CN102526274A (en) | 2010-12-31 | 2010-12-31 | Traditional Chinese medicine for treating chronic hepatitis and hepatic fibrosis |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2010106184123A CN102526274A (en) | 2010-12-31 | 2010-12-31 | Traditional Chinese medicine for treating chronic hepatitis and hepatic fibrosis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN102526274A true CN102526274A (en) | 2012-07-04 |
Family
ID=46335095
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2010106184123A Pending CN102526274A (en) | 2010-12-31 | 2010-12-31 | Traditional Chinese medicine for treating chronic hepatitis and hepatic fibrosis |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102526274A (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103720826A (en) * | 2013-12-23 | 2014-04-16 | 广西盈康药业有限责任公司 | Method for preparing radix prismatomeris connatae tablet |
| CN104922247A (en) * | 2015-06-08 | 2015-09-23 | 广西壮族自治区民族医药研究院 | Extraction method and application of ethyl acetate extract of Prismatomeris tetrandra |
| CN113181256A (en) * | 2021-04-29 | 2021-07-30 | 广西中医药大学制药厂 | Chinese medicinal composition for treating hepatic fibrosis |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1718225A (en) * | 2004-07-07 | 2006-01-11 | 庞国 | Compound traditional Chinese medicine for treating hepatic lesion, and its prepn. method |
| CN101028374A (en) * | 2007-01-15 | 2007-09-05 | 广西中医学院 | Chinese-medicinal preparation for treating liver diseases and its use |
-
2010
- 2010-12-31 CN CN2010106184123A patent/CN102526274A/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1718225A (en) * | 2004-07-07 | 2006-01-11 | 庞国 | Compound traditional Chinese medicine for treating hepatic lesion, and its prepn. method |
| CN101028374A (en) * | 2007-01-15 | 2007-09-05 | 广西中医学院 | Chinese-medicinal preparation for treating liver diseases and its use |
Non-Patent Citations (1)
| Title |
|---|
| 周程艳等: "黄根化学成分与药理作用的研究进展", 《广西中医学院学报》, vol. 9, no. 4, 31 December 2006 (2006-12-31) * |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103720826A (en) * | 2013-12-23 | 2014-04-16 | 广西盈康药业有限责任公司 | Method for preparing radix prismatomeris connatae tablet |
| CN103720826B (en) * | 2013-12-23 | 2016-06-22 | 广西盈康药业有限责任公司 | A kind of preparation method of xanthorrhiza sheet |
| CN104922247A (en) * | 2015-06-08 | 2015-09-23 | 广西壮族自治区民族医药研究院 | Extraction method and application of ethyl acetate extract of Prismatomeris tetrandra |
| CN104922247B (en) * | 2015-06-08 | 2019-02-19 | 广西壮族自治区民族医药研究院 | A kind of extracting method and application of the ethyl acetate extract of xanthorrhiza |
| CN113181256A (en) * | 2021-04-29 | 2021-07-30 | 广西中医药大学制药厂 | Chinese medicinal composition for treating hepatic fibrosis |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102600423B (en) | Preparation method of Chinese medicine for treating hepatic fibrosis | |
| CN103083443B (en) | Chinese medicinal composition for treating arthritis and preparation method thereof | |
| CN109045201A (en) | For treating chronic digestible tract disease with the Chinese medicine composition of anxiety-depression state | |
| CN103285119B (en) | Chinese medicine composition for treating autoimmune liver disease, and preparation method thereof | |
| CN102210836A (en) | Application of Chinese medicinal composition in preparation of medicine for treating stomach cancer | |
| CN101947300A (en) | Traditional Chinese medicinal composition for treating liver diseases, preparation method thereof and use thereof | |
| CN102727687B (en) | Medicine treating chronic fatigue syndrome and its application | |
| CN102526274A (en) | Traditional Chinese medicine for treating chronic hepatitis and hepatic fibrosis | |
| CN102885928B (en) | Chinese medicinal injection for treating jaundice and preparation method thereof | |
| CN102309705B (en) | Medicine for reducing serum uric acid, preparation method thereof and purpose thereof | |
| CN101850063A (en) | Medicinal preparation for preventing and treating gout and preparation method | |
| CN103028092A (en) | Medicine for regulating liver regeneration and preparation method of medicine | |
| CN103041288B (en) | A kind of Chinese medicine composition and preparation technology treating diabetic fatty liver | |
| CN109925469B (en) | Traditional Chinese medicine composition for treating liver-stagnation and spleen-deficiency type non-alcoholic fatty liver disease and application thereof | |
| CN105902774A (en) | Chinese medicinal composition, preparation method thereof and application in preparation of drugs for treatment of acute gouty arthritis | |
| CN105617335A (en) | Radix bupleurum Xianxiong decoction capable of improving bile reflux gastritis after cancer chemoradiotherapy | |
| CN104257960A (en) | Traditional Chinese medicine composition for treating non-alcoholic fatty liver disease and applications of composition | |
| CN100500203C (en) | Medicine for treating fatty liver and its preparation method | |
| CN104352633A (en) | Preparation method of pharmaceutical composition for treating osteoarthrosis | |
| CN104888121A (en) | Traditional Chinese medicine extract for adjuvant therapy of pelvic inflammation, preparation method and application of traditional Chinese medicine extract, and body cream | |
| CN109692203A (en) | A kind of pharmaceutical composition with antigout effect | |
| CN104096130A (en) | Traditional Chinese medicine composition for treating rheumatoid arthritis | |
| CN101979084B (en) | Chinese medicinal composition for warming kidney and tonifying yang and preparation method thereof | |
| CN103550409B (en) | Pharmaceutical composition of a kind of fat-reducing and preparation method thereof | |
| CN114869956B (en) | Pharmaceutical composition for treating post-stroke dyskinesia, and preparation method and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C12 | Rejection of a patent application after its publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20120704 |